Prosecution Insights
Last updated: September 17, 2026
Application No. 18/870,903

ORGANIC DISELENIDE COMPOSITION

Non-Final OA §112
Filed
Dec 02, 2024
Priority
Jun 01, 2022 — CIP of PCTUS2022031687 +1 more
Examiner
ROCHELLE, CIERRA MARIE
Art Unit
Tech Center
Assignee
Selenbio Inc.
OA Round
1 (Non-Final)
100%
Grant Probability
Favorable
1-2
OA Rounds
10m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 100% — above average
100%
Career Allowance Rate
3 granted / 3 resolved
+40.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
19 currently pending
Career history
8
Total Applications
across all art units

Statute-Specific Performance

§101
8.3%
-31.7% vs TC avg
§103
41.7%
+1.7% vs TC avg
§102
5.0%
-35.0% vs TC avg
§112
18.3%
-21.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 3 resolved cases

Office Action

§112
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement No Information Disclosure Statement has been filed. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2 and 3 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 2 is a “method of preventing and/or treating a surface”, but does not include any active method steps. It is unclear how the compound is being used to treat the surface, and if the compound is being applied to the surface. Also, it is unclear whether the surface comprises the biocidal agent, also comprises the compound, or if the compound is applied to the surface. It is also unclear what is being prevented and/or treated on the surface. Claim 3 recites “A composition for incorporation with one or more polymers…process” and then recites “the composition including one or more polymers as a substrate”. The first phrase seems to imply a step of adding polymers to a composition using a chemical bonding step, while the 2nd phrase simply requires a substrate, one or more polymers and the claimed diselenide. The claim is interpreted as a composition that is chemically bonded with one or more polymers, and a separate composition comprising one or more polymers that act as a substrate to support organic diselenide. The two phrases recite distinct structural characteristics which render the metes and bounds of the claim indefinite and it is unclear what specific structure applicant is limiting the claims too. Allowable Subject Matter Claim 1 is allowed. Closest Prior Art The closest prior art is Tian (Fengshou Tian et al., “Efficient Reductive Selenation of Aromatic Aldehydes to Symmetrical Diselenides with Se/CO/H2O under Atmospheric Pressure”, The Journal of Organic Chemistry, 20 May 2004, Pgs. 4520-4523, as cited on the International Search Report (ISR) dated 01 June 2021). Tian teaches organic diselenides useful as synthetic reagents and chemical intermediates (Abstract). Tian teaches compound 2b, bottom left, that overlaps with the diselenide compound in the instant claims, bottom right. PNG media_image1.png 85 317 media_image1.png Greyscale PNG media_image2.png 222 505 media_image2.png Greyscale Compound 2b disclosed in Tian does not teach additional carbon atoms, or double bonds, as in the instant diselenide compound. It would not have been prima facie obvious for one of ordinary skill in the art before the effective filing date to add 2 additional carbon-carbon double bonds to each side of the selenide compound disclosed in Tian because there is no known motivation in the art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CIERRA M ROCHELLE whose telephone number is (571)272-9962. The examiner can normally be reached Mon-Fri 8:00-5:00 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.M.R./Examiner, Art Unit 1627 /JENNIFER A BERRIOS/ Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Dec 02, 2024
Application Filed
Aug 20, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12723046
cGAS INHIBITORS
2y 8m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
100%
Grant Probability
99%
With Interview (+0.0%)
2y 7m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 3 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month